LRRK2 and Parkinson disease: As mentioned above, LRRK2 has been reported to co-localize with microtubules under overexpression conditions (7, 43), an association that is enhanced by most of the common PD-linked mutations (33, 43) and by treatment with Type I kinase inhibitors (36).